VivoSim Labs, Inc. (VIVS) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on August 14, 2025, by VivoSim Labs, Inc., a Delaware corporation headquartered in San Diego, California. The Company develops organ-specific 3D models combined with AI-driven analytics to provide decision-ready insights for life science development. The report primarily addresses the appointment of a new executive officer.
Key Financial Metrics
The filing does not provide financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on executive compensation and appointment details.
Material Changes
On August 7, 2025, the Board of Directors appointed Tony Lialin as Chief Commercial Officer, effective August 11, 2025. Mr. Lialin brings over two decades of experience in scaling life science platforms and forging pharma partnerships. His prior roles include Chief Commercial Officer at DPBIO and Invivoscribe, Inc., and Vice President roles at Seonix Bio and ONI.
Compensation and Equity Grant
- Base Salary: $360,000 annualized.
- Sign-on Bonus: $10,000.
- Target Incentive: Up to 40% of base salary, subject to the Company's bonus plan.
- Equity Grant: Option to purchase 40,000 shares of common stock under the 2022 Equity Incentive Plan.
- Vesting Schedule: 25% vests on August 11, 2026, with the remainder vesting in 12 equal quarterly installments thereafter.
- Employment Status: At-will basis.
Outlook and Risks
Management commentary indicates Mr. Lialin will lead go-to-market strategy, partnerships, and the expansion of the Company's San Diego-based services. The filing does not disclose specific risks, contingencies, or unusual items beyond standard employment terms. No guidance regarding future financial performance is provided in this document.
Investor Verification Checklist
- Verify the full text of the Offer Letter (Exhibit 10.1) for additional compensation terms or conditions not summarized here.
- Review the press release (Exhibit 99.1) for broader strategic context regarding the new leadership appointment.
- Confirm the Company's current cash position and runway in the most recent 10-Q or 10-K, as this 8-K does not contain liquidity data.
- Monitor future filings for the impact of the new Chief Commercial Officer on revenue growth and partnership announcements.